Profile data is unavailable for this security.
About the company
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
- Revenue in CNY (TTM)508.01m
- Net income in CNY40.23m
- Incorporated2005
- Employees907.00
- LocationGuangzhou LBP Medicine Science & Technology Co LtdNo. 2, Kexin Street, Fengxin RoadScience City, Huangpu DistrictGUANGZHOU 510663ChinaCHN
- Phone+86 2 032210051
- Fax+86 2 032290284
- Websitehttp://www.gzlbp.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Rendu Biotechnology Co Ltd | 170.46m | 18.36m | 1.26bn | 358.00 | 68.49 | 1.31 | -- | 7.38 | 0.4589 | 0.4589 | 4.26 | 23.90 | 0.1618 | 1.12 | 2.16 | 476,147.80 | 1.74 | 6.26 | 1.88 | 7.17 | 80.80 | 74.36 | 10.77 | 14.54 | 11.85 | -- | 0.0066 | 7.96 | -45.89 | 18.85 | -64.60 | -- | 23.48 | -- |
| Shanghai Rightongene Biotechnlgy Co Ltd | 265.52m | 7.17m | 1.33bn | 501.00 | 179.46 | 1.43 | -- | 5.03 | 0.1332 | 0.1332 | 4.75 | 16.67 | 0.2540 | 1.09 | 1.40 | 529,970.30 | -0.0901 | 4.16 | -0.098 | 4.49 | 75.02 | 70.45 | -0.3548 | 11.62 | 10.43 | -- | 0.0284 | 5.90 | -39.14 | 2.84 | -80.41 | -11.46 | 19.65 | -- |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 676.54m | -33.28m | 1.39bn | 952.00 | -- | 1.46 | -- | 2.05 | -0.3332 | -0.3332 | 6.77 | 9.51 | 0.3477 | 2.87 | 3.56 | 710,646.30 | -3.16 | -0.1562 | -4.44 | -0.1991 | 26.58 | 40.00 | -9.10 | -0.4907 | 0.6901 | -0.3569 | 0.3665 | 95.15 | 36.92 | 12.37 | 58.52 | -- | 66.95 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 192.49m | 37.23m | 1.44bn | 321.00 | 38.66 | 1.32 | -- | 7.48 | 0.3441 | 0.3441 | 1.78 | 10.05 | 0.1689 | 0.9282 | 6.82 | 599,656.40 | 3.27 | 10.43 | 3.32 | 10.84 | 75.08 | 80.54 | 19.34 | 32.57 | 50.03 | -- | 0.0119 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Guangzhou LBP Medicine Scnc&Tech Co Ltd | 508.01m | 40.23m | 1.60bn | 907.00 | 39.89 | 1.26 | -- | 3.15 | 0.4292 | 0.4292 | 5.32 | 13.61 | 0.3719 | 2.12 | 2.15 | 560,104.20 | 1.83 | 5.10 | 1.91 | 5.55 | 67.83 | 75.15 | 4.91 | 12.97 | 6.70 | -- | 0.0068 | 24.42 | -1.99 | 10.18 | -6.18 | -8.21 | -2.98 | -- |
| Zhejiang Shengda Bio-pharm Co Ltd | 742.96m | -53.74m | 1.85bn | 1.03k | -- | 1.48 | -- | 2.49 | -0.3325 | -0.3325 | 4.27 | 7.31 | 0.4409 | 2.33 | 6.08 | 719,919.20 | -3.10 | 3.39 | -3.71 | 4.42 | 15.03 | 28.58 | -7.02 | 7.57 | 1.41 | -- | 0.2268 | 39.98 | -1.44 | 8.10 | -271.70 | -- | 11.22 | -6.89 |
| Holder | Shares | % Held |
|---|---|---|
| Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 502.17k | 2.37% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 490.83k | 2.32% |
| Broad Fund Management Co. Ltd.as of 31 Dec 2023 | 471.86k | 2.23% |
| Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 2023 | 319.80k | 1.51% |
| Goldstate Capital Fund Management Co., Ltd.as of 31 Dec 2023 | 307.66k | 1.45% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 274.85k | 1.30% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 269.79k | 1.27% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 171.94k | 0.81% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 96.74k | 0.46% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 91.91k | 0.43% |
